Stock Track | Arcutis Biotherapeutics (ARQT) Soars 9.18% Pre-Market on Stellar Q4 Results, Driven by Robust ZORYVE Sales

Stock Track

Feb 26, 2025

Arcutis Biotherapeutics Inc. (ARQT) witnessed a significant pre-market surge of 9.18% on Wednesday, following the release of its impressive fourth quarter 2024 financial results.

The biopharmaceutical company's strong performance was fueled by robust sales growth of its flagship product ZORYVE, a topical PDE4 inhibitor approved for multiple inflammatory skin conditions. ZORYVE's net product revenue surged 413% year-over-year to $69.4 million in Q4, driven by growing demand across its approved indications of plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.

ZORYVE has rapidly gained market share and is now the most prescribed branded non-steroidal topical treatment across these three major inflammatory skin conditions in the United States. The company's total revenue for Q4 came in at $71.4 million, beating analysts' estimates, while its reported loss per share also surpassed expectations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1142565345"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142565345\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142565345?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 18:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142565345","market":"us","top_or_hot":-1,"title":"Stock Track | Arcutis Biotherapeutics (ARQT) Soars 9.18% Pre-Market on Stellar Q4 Results, Driven by Robust ZORYVE Sales","media":"Stock Track","content":"<p>Arcutis Biotherapeutics Inc. (ARQT) witnessed a significant pre-market surge of 9.18% on Wednesday, following the release of its impressive fourth quarter 2024 financial results.</p>\n\n<p>The biopharmaceutical company's strong performance was fueled by robust sales growth of its flagship product ZORYVE, a topical PDE4 inhibitor approved for multiple inflammatory skin conditions. ZORYVE's net product revenue surged 413% year-over-year to $69.4 million in Q4, driven by growing demand across its approved indications of plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.</p>\n\n<p>ZORYVE has rapidly gained market share and is now the most prescribed branded non-steroidal topical treatment across these three major inflammatory skin conditions in the United States. The company's total revenue for Q4 came in at $71.4 million, beating analysts' estimates, while its reported loss per share also surpassed expectations.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arcutis Biotherapeutics (ARQT) Soars 9.18% Pre-Market on Stellar Q4 Results, Driven by Robust ZORYVE Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arcutis Biotherapeutics (ARQT) Soars 9.18% Pre-Market on Stellar Q4 Results, Driven by Robust ZORYVE Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-26 18:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arcutis Biotherapeutics Inc. (ARQT) witnessed a significant pre-market surge of 9.18% on Wednesday, following the release of its impressive fourth quarter 2024 financial results.</p>\n\n<p>The biopharmaceutical company's strong performance was fueled by robust sales growth of its flagship product ZORYVE, a topical PDE4 inhibitor approved for multiple inflammatory skin conditions. ZORYVE's net product revenue surged 413% year-over-year to $69.4 million in Q4, driven by growing demand across its approved indications of plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.</p>\n\n<p>ZORYVE has rapidly gained market share and is now the most prescribed branded non-steroidal topical treatment across these three major inflammatory skin conditions in the United States. The company's total revenue for Q4 came in at $71.4 million, beating analysts' estimates, while its reported loss per share also surpassed expectations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARQT","symbol_name":"Arcutis Biotherapeutics Inc.","start_time":0,"source_url":"","article_id":"1142565345","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142565345","pubTimestamp":1740567325,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arcutis Biotherapeutics Inc.  witnessed a significant pre-market surge of 9.18% on Wednesday, following the release of its impressive fourth quarter 2024 financial results.The biopharmaceutical company's strong performance was fueled by robust sales growth of its flagship product ZORYVE, a topical PDE4 inhibitor approved for multiple inflammatory skin conditions. ZORYVE's net product revenue surged 413% year-over-year to $69.4 million in Q4, driven by growing demand across its approved indicatio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARQT":"Arcutis Biotherapeutics Inc."},"translate_title":"在ZORYVE强劲销售的推动下，Arcutis Biotherapeutics(ARQT)第四季度业绩出色，盘前股价飙升9.18%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1},"content_text":"Arcutis Biotherapeutics Inc. (ARQT) witnessed a significant pre-market surge of 9.18% on Wednesday, following the release of its impressive fourth quarter 2024 financial results.\nThe biopharmaceutical company's strong performance was fueled by robust sales growth of its flagship product ZORYVE, a topical PDE4 inhibitor approved for multiple inflammatory skin conditions. ZORYVE's net product revenue surged 413% year-over-year to $69.4 million in Q4, driven by growing demand across its approved indications of plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.\nZORYVE has rapidly gained market share and is now the most prescribed branded non-steroidal topical treatment across these three major inflammatory skin conditions in the United States. The company's total revenue for Q4 came in at $71.4 million, beating analysts' estimates, while its reported loss per share also surpassed expectations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}